JCO oncology practice 2023 May 19
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules.
ABSTRACT
[Media: see text].
Related Questions
Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts?
Are ther...
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (August 4, 2024)
Pulmonary toxicity of T-DXd may represent off-target toxicity, as other DXd-based ADCs, anti-Trop2 datopotamab deruxtecan, and the anti-HER3 patritumab deruxtecan are capable ...